Strategic funding Zafrens recently closed a Series A financing of 31 million, signaling strong investor confidence and available capital to accelerate partnerships, collaborative R&D programs, and early access deals for its high-throughput single-cell platform.

Platform leverage The Z-Screen ultra-high throughput platform enables full multi-omics characterization and direct linking of molecular profiles to cell phenotype, offering a compelling value prop for pharma and biotech clients seeking accelerated drug discovery and target validation.

Pipeline potential Beyond platform development, Zafrens is actively developing its own drug candidates, presenting opportunities for co-development, licensing, or early access collaboration with interested partners looking to diversify their early-stage pipelines.

Strategic investors Notable investors and funds involved include Mitsui Chemicals, Global Brain, Prime Movers Lab, BlueYard Capital and others, which can facilitate strategic partnerships, cross-border collaboration, and potential co-investment pathways.

Market positioning With a focused biotechnology niche in high-throughput single-cell analysis and multi-omics, Zafrens sits at the intersection of cell biology, genomics, and drug discovery, presenting a target for partnerships with CROs, academic hubs, and pharmaceutical companies pursuing next-gen throughput capabilities.